DDInter44 DDInter915
Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck. It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Alfuzosin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Alfuzosin {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Alfuzosin {u} (Compound) upregulates {v} (Gene) PAK1
PAK1 {u} (Gene) is upregulated by {v} (Compound) Procaterol
Procaterol {u} (Compound) resembles {v} (Compound) Indacaterol
Alfuzosin {u} (Compound) downregulates {v} (Gene) USP22
USP22 {u} (Gene) is downregulated by {v} (Compound) Procaterol
Procaterol {u} (Compound) resembles {v} (Compound) Indacaterol
Alfuzosin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Alfuzosin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) binds {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Alfuzosin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Formoterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Adrenergic beta2-Agonists {u} (Pharmacologic Class) includes {v} (Compound) Indacaterol
Alfuzosin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pseudoephedrine
Pseudoephedrine {u} (Compound) palliates {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Alfuzosin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Formoterol {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Alfuzosin {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Vemurafenib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Alfuzosin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Alfuzosin (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Indacaterol (Compound)
Alfuzosin (Compound) upregulates PAK1 (Gene) and PAK1 (Gene) is upregulated by Procaterol (Compound) and Procaterol (Compound) resembles Indacaterol (Compound)
Alfuzosin (Compound) downregulates USP22 (Gene) and USP22 (Gene) is downregulated by Procaterol (Compound) and Procaterol (Compound) resembles Indacaterol (Compound)
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Indacaterol (Compound)
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class) and Adrenergic beta2-Agonists (Pharmacologic Class) includes Indacaterol (Compound)
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine (Compound) palliates asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Indacaterol (Compound)
Alfuzosin may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)